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Objectives
• Osteoporosis mainly concerns postmenopausal women • Osteoporosis increases the risk of (low trauma) fractures • Main fracture localisations are distal forearm, spine and femoral neck • Osteoporosis can be treated by calcium, hormone replacement therapy and therapy with biphosphonates • Diagnosis of osteoporosis covers clinical parameters and the measurement of bone density • Gold standard for the measurement of bone density is the dual X-ray absorptiometry (DXA) • Qualitative ultrasound (QUS) as a non-invasive and radiationfree technology is becoming more important in the diagnosis of osteoporosis
On behalf of the German Agency for Health Technology Assessment (DAHTA@DIMDI) a rapid health economic Health Technology Assessment (HTA) was conducted to examine the cost-effectiveness of QUS as a technique for screening and diagnosing osteoporosis and subsequently for the prevention of osteoporotic fractures

Methods
The rapid health economic HTA was conducted according to the german methodological recommendations for rapid health economic HTA developed by the authors (1 
Results
Four publications (2-5) dealt with the question of the costeffectiveness of QUS as a screening instrument in a two-step proceeding. Study population in all studies have been postmenopausal women of different age groups. Age groups and quantitative parameters are shown in table 1. All publications showed methodological weaknesses, especially in the consideration of relevant economic parameters. Nevertheless cost data of three studies (3-5) could be used for own calculations of incremental cost-effectiveness ratios. An additional case diagnosed by DXA in a one-step proceeding rises costs of 1.000 Euro.
Conclusion
A priorisation of a two-step or a one-step proceedig is not possible at present due to missing data and the lack of evidence. Decision analytic models considering long-term effects are recommended. Langton Table 2 demonstrates the calculation of a monetary cut-off point in a two-step proceeding. A two-step proceeding with QUS is costeffective as long as the costs of one QUS examination are lower than 31%-51% of the costs of one DXA examination (51% reported by Lippuner et al.) First experiences with the conduction of rapid health economic Health Technology Assessments 
A rapid health economic HTA is the assessment of a technology under economic aspects with a targeted question.Therefore rapid health economic HTAs are indicated for restricted questions with high priority by decision makers. The conduction of a rapid health economic HTA demands careful considerations. In cooperation with the potential adressee the study question should be focussed. In some cases, especially in the case a decision analysis is demanded rapid health economic HTA will not be the appropriate instrument for its own, but should be used in combination with comprehensive HTA. Further research is needed. More rapid health economic HTAs should be conducted following the methodological recommendations accompanied by a systematic quality assessment. Further experiences might result in a revision of the methodological recommendations. 
Methods
Development of methodological recommendations
Objectives
• Decision analytic modelling is a method to evaluate the costeffectiveness of an intervention considering short and long term effects and costs. Therefore data of different sources and of different evidence is used. In decision analytic modelling patients might change health states until they die due to disease specific causes or due to unspecified causes (reflecting background mortality). All health states will have a specific health outcome (e.g. QALY) and specific costs.
• Treatment costs in the last two years before dying are exeptionally high. In a decision analytic model this fact should be accounted for by adding costs due to dying once a patient is changing from one health state to the health state ‚death due to disease specific causes' or ‚death due to unspecified causes'. Research objective was to calculate terminal costs for disease specific causes (e.g. Hepatitis C related causes) and unspecified causes (‚background mortality')
Methods
The general idea was to calculate the costs of the last inpatient treatment before death and to add these costs once, in the moment a patient is entering the health states "death of unspecified causes" or "death of disease specific causes". Procedure Costs were calculated by multiplying the hospital length-of-stay of the terminal inpatient treatment with administrative per diem costs consisting of prices of general rate and departemental rate (internal medicine used for patients ≥15years and pediatrics for patient <15 years). The determination of hospital length-of-stay varied. In a first step age was not considered. In the calculation of costs due to "death of unspecified causes" the most common diagnoses (with a coverage of 75% of all death in the year 1999) have been considered. The average hospital length-of-stay was calculated by weighting the hospital lengh-of-stay of one disease by the proportion of patients that died of this disease. The calculation of age specific costs of dying of unspecified causes considered the ten most common diagnoses in the particular age group. Costs due to "disease specific causes" have been calculated at the example of Hepatitis C related diseases. All relevant ICD 9 codes have been identified first. For these diagnosis non age specific and age specific costs have been calculated as described above. 
Conclusion
The demonstrated approach is a pragmatic way to assess terminal costs due to dying of different causes using preexisting statistical data. It is easily transferable and adaptable for different decision analytic models in the german health care sector. Nevertheless a couple of limitations exist. Costs due to dying are still underestimated, as just the additional costs in consequence of the last inpatient treatment before death are considered. As it is shown in the literature costs before death will rise in the last two or three years of life. In the cost calculation just the departemental rate of an internal ward have been considered for all cases. By ignoring e.g. surgical ward and intensive care units prices are underestimated. The statistical data of the Federal Statistical Office Germany are based on the year 1999. Hospital length-of-stay as well as the number of death due to a specific disease will not have altered significantly in the last 5 years. For this reason the bias is expected to be of low effect. Due to the taken perspective costs for outpatient treatment and and home care are not considered but certainly will contribute to the terminal costs to a high percentage. Further research is necessary to evaluate the real costs in the terminal years for the whole population and for specific diseases. 
